Related Experiment Video

Updated: Aug 7, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.3K

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

Anitta Shaji1, Doody Thomas1, Midhuna Saju1

  • 1Nirmala College of Pharmacy, Muvattupuzha, Kerala, India.

Perspectives in Clinical Research
|March 13, 2023
PubMed

Insights

Dabigatran alone effectively reduced stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. Combining dabigatran with antiplatelets showed higher baseline risks compared to dabigatran monotherapy.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dabigatran, a direct thrombin inhibitor, is FDA-approved for preventing embolic events in nonvalvular atrial fibrillation.
  • Patient dosing is guided by CHA2DS2-VASc and HAS-BLED scores.

Purpose of the Study:

  • To assess and compare stroke and bleeding risks following dabigatran initiation.
  • To evaluate the impact of concomitant antiplatelet use on dabigatran's safety and efficacy.

Main Methods:

  • Retrospective study of 75 adult patients prescribed dabigatran between 2017-2019.
  • Comparison of clinical outcomes between patients receiving dabigatran alone versus dabigatran with an antiplatelet.

Main Results:

  • Both groups showed significant reductions in CHA2DS2-VASc and HAS-BLED scores within 6 months.
  • The dabigatran alone group had lower baseline stroke and bleeding risk scores compared to the dabigatran plus antiplatelet group.

Conclusions:

  • Dabigatran therapy, with or without antiplatelets, reduced risk scores within 6 months.
  • Dabigatran monotherapy demonstrated a lower background risk profile for stroke and bleeding than combination therapy.
Abstract

Keywords:
Antiplateletbleeding riskdabigatranoral anticoagulantthromboembolic events

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.1K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
802
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
14
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
21
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
18
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K